Pulsenmore

Pulsenmore R&D / Revenue

The R&D to Revenue Ratio of Pulsenmore (PLSM.TA) as of Nov 4, 2026 is 43.35 %. In the previous year, R&D to Revenue Ratio was 195.73 % — a change of -77.85% (lower).

R&D / Revenue

43.35 %

YoY

-77.85%

Last updated:

R&D to Revenue Ratio of Pulsenmore is 2025 43.35 % . R&D to Revenue Ratio of Pulsenmore was 2024 195.73 % . It decreases by -77.85% lower compared to the previous year.

The Pulsenmore R&D / Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D / Revenue
Date
R&D / Revenue
Jan 1, 2021
672.69 ILS
Jan 1, 2022
266.95 ILS
Jan 1, 2023
490.05 ILS
Jan 1, 2024
195.73 ILS
Jan 1, 2025
43.35 ILS
The Pulsenmore R&D / Revenue history
YEARR&D / RevenueYoY
43.35 %-77.85%
195.73 %-60.06%
490.05 %+83.57%
266.95 %-60.32%
672.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pulsenmore Stock analysis

What does Pulsenmore do? Pulsenmore Ltd. generates revenue through the sale of its two miniaturized ultrasound systems, PulseNmore ES and PulseNmore FC, designed for home use in remote clinical diagnosis. The PulseNmore ES targets pregnant women requiring regular ultrasound monitoring, while PulseNmore FC caters to women undergoing in vitro fertilization needing follicle size assessments. Both systems integrate with smartphones, enabling patients to conduct tests at home and share results online with healthcare providers. The company also monetizes through software delivery for its devices, enhancing user experience and data management. The primary buyers of PulseNmore ES are pregnant women seeking convenient, clinic-free monitoring, and healthcare providers managing prenatal care remotely. PulseNmore FC is purchased by women undergoing in vitro fertilization, often through fertility clinics or medical centers that recommend the device. These segments value the convenience of home-based diagnostics and seamless telehealth integration without requiring in-person visits. Pulsenmore Ltd. focuses on global markets for its portable ultrasound solutions, serving patients in remote or underserved areas who benefit from telehealth-enabled diagnostics. The company’s products are positioned as cost-effective alternatives to traditional clinic visits, appealing to both end-users and healthcare institutions aiming to reduce operational costs while maintaining patient care quality. Pulsenmore is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulsenmore stock

R&D to Revenue Ratio of Pulsenmore is 43.35 % in 2025.

R&D to Revenue Ratio of Pulsenmore changed from 195.73 % to 43.35 %, representing a -77.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D to Revenue Ratio Pulsenmore since 2006 – with annual values, charts, and detailed analysis.

The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.

A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's Pulsenmore with sector peers and the industry average to assess whether it is attractive.

To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Pulsenmore

All Key Metrics — Pulsenmore